Experimental eczema drug tested in healthy people – but trial halted

NCT ID NCT05288543

Terminated Knowledge-focused Sponsor: Nanjing Immunophage Biotech Co., Ltd Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This was a very early (Phase 1) study to check the safety of an experimental drug called IPG7236, taken as a pill. The study involved 63 healthy adults aged 18 to 55. The goal was to see how the body handles the drug and if it causes side effects, before testing it in people with atopic dermatitis (eczema). The trial was terminated, so its findings may be incomplete.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: IPG7236 (an experimental oral drug)
What this could lead to: If successful, this early study could pave the way for further testing of IPG7236 as a potential treatment for atopic dermatitis.
What could go wrong: This is a very early Phase 1 trial in healthy volunteers, not patients. The study was terminated, so results may be limited. It is too soon to know if IPG7236 will be safe or effective for treating any disease.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ATOPIC DERMATITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

atopic eczema

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ATOPIC DERMATITIS

Contacts and locations

Locations

Scientia Clinical Research Ltd

Randwick, New South Wales, 2031, Australia

More trials for these conditions

Other studies related to the condition(s) this trial covers.